Copyright
©The Author(s) 2005.
World J Gastroenterol. Aug 7, 2005; 11(29): 4484-4489
Published online Aug 7, 2005. doi: 10.3748/wjg.v11.i29.4484
Published online Aug 7, 2005. doi: 10.3748/wjg.v11.i29.4484
Table 2 Rate (number responding/total treated) of patients with negative viremia during the course of the trial
| Screening | T4 | T8 | T12 | T18 | T24 | T48 | |
| r-hIFN β-1a | 0 | 18 | 16 | 21 | 16 | 15 | 11 |
| (n = 51) | 0% | -35.30% | -31.40% | -41.20% | -31.40% | -29.40% | -21.56% |
| r-hIFN β-1a + ribavirin | 0 | 13 | 22 | 24 | 21 | 21 | 14 |
| (n = 51) | 0% | -25.50% | -43.10% | -47.10% | -41.20% | -41.20% | -27.45% |
- Citation: Pellicano R, Craxì A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11(29): 4484-4489
- URL: https://www.wjgnet.com/1007-9327/full/v11/i29/4484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i29.4484